Stocktoria

GT Biopharma, Inc. GTBP

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2013-10-22

GT Biopharma, Inc. statistics & valuation

Market cap$18.2M
P / B3.1×
Dividend yield1.26%
Return on capital-214.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
2016201720182019202020212022202320242025
Return on equity (%)
-57.30% -2279.60% -264.80% -178.00% -101.60% -490.00% 2016201720182019202020212022202320242025
Shares outstanding
104218 50.1M 50.7M 4.1M 5.2M 32.1M 1.1M 1.4M 2.2M 25.5M 2016201720182019202020212022202320242025
Net debt ($)
2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
39072.00% -56.70% -1020.50% -9759.30% -499.80% -180.30% -124.80% -53.80% -311.00% -349.80% 2016201720182019202020212022202320242025
Free cash flow margin (%)
2016201720182019202020212022202320242025
Debt / equity (×)
2016201720182019202020212022202320242025
EPS ($)
$119.91 -$8.60 -$5.16 -$19.66 -$5.64 -$6.94 -$6.68 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Return on assets-349.8%-311.0%-53.8%-124.8%-180.3%-499.8%-9759.3%-1020.5%-56.7%39072.0%
Return on equity-490.0%788.1%-101.6%-178.0%-264.8%96.1%200.1%-2279.6%-57.3%-51.6%
Current ratio3.500.722.123.353.140.160.010.010.220.00

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.